| 0.7981 -0.202 (-20.19%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Marrone Bio Innovations, Inc. (MBII) specializes in the creation, development, and commercialization of biologically-derived products for use in agriculture. The company's product line is strategically designed to bolster crop protection, improve overall plant vitality, and provide essential nutrition for various crops. Their extensive portfolio includes solutions such as Emergen, Foramin (and its ST variant), Optima, Takla, Pacesetter, Ympact, and UBP (and its ST variant), all engineered to enhance crop health, maximize yields, and improve the final quality of produce. For pest control, MBII offers Grandevo, a bioinsecticide that targets sucking and chewing insects, and Venerate, another bioinsecticide effective against a range of chewing and sucking insects, as well as mites. To combat environmental stressors, Haven is available as a plant health product formulated to reduce sun-induced stress and combat dehydration. Furthermore, their Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers play a crucial role in preventing, managing, and eliminating algal, fungal, and bacterial diseases throughout both the agricultural and horticultural sectors. The company also supplies bionematicides like Majestene, which controls soil-dwelling nematodes and certain soil-borne insects, and Zelto, specifically formulated to protect turf areas, including golf course fairways and greens, by promoting robust plant and root health. Rounding out their offerings are Regalia and Stargus, products that deliver defense against fungal and bacterial diseases while concurrently boosting crop yields and quality. Marrone Bio Innovations distributes its offerings through a blended approach, employing a direct sales force in addition to working with distributors and various commercial partners. The company, initially incorporated in 2006 under the name Marrone Organic Innovations, Inc., is headquartered in Raleigh, North Carolina.
Thu, 02 Mar 2023
Keith Mcgovern Net Worth (2026) - GuruFocus
Mon, 19 Dec 2022
Stuart Woolf Net Worth (2026) - GuruFocus
Tue, 01 Nov 2022
Philip J Hempleman Net Worth (2026) - GuruFocus
Wed, 16 Mar 2022
Marrone Bio Innovations, an Ospraie Ag Science Portfolio Company, To Be Acquired for $236 Million - Pryor Cashman LLP
Wed, 23 Feb 2022
Marrone Bio Appoints LaDon Johnson As Interim CFO - citybiz.co
Thu, 14 May 2020
Marrone Bio Innovations receives first approval for REGALIA MAXX for cannabis and hemp in Canada - Proactive financial news
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Basic Materials
|
|
|
Industry:
Agricultural Inputs
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|